A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

Completed · Phase 1

Conditions studied: Cancer

In brief

This is a Phase I study which will analyze any food-drug effects as well as QTc effects of perifosine. Safety and efficacy will also be evaluated. Patients who complete the first 24 days on single agent perifosine may have the opportunity to 1) continue on single agent perifosine; 2) switch to the combination of capecitabine + perifosine; or 3) switch to the combination of sorafenib + perifosine.

Key facts

Study ID

NCT01224730

Run by

AEterna Zentaris

People needed

24

Starts

2012-01-24

Expected to finish

2013-11-04

Last updated by the study team

2018-03-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced malignancies
• Patients with adequate organ and marrow function

You may not qualify if…

• Patients previously treated with perifosine
• Patients receiving any other chemotherapy, targeted agents, investigational agents or devices within four weeks (28 days) prior to Day 1 of study treatment

Where it is running

• Study site — Dallas, Texas, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.